BCL2 and ovarian cancer: A recent study by Tayama S, et al. provided evidence that EpCAM overexpression is an independent risk factor for chemoresistance, and correlated with a lower level of cisplatin-induced apoptosis, which is regulated by EpCAM-Bcl-2 axis in ovarian cancer [23].